دورية أكاديمية
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia.
| العنوان: | Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia. |
|---|---|
| المؤلفون: | Campbell D; Assistant Director, Scientific Consulting, Scientific Consulting, Xcenda, Palm Harbor, FL., Blazer M; Associate Director, Scientific Consulting, Xcenda, Palm Harbor, FL., Bloudek L; President, Curta, Seattle, WA., Brokars J; Health Outcomes Research Director, Worldwide Health Economics and Outcomes Research Communications Lead, Bristol-Myers Squibb, Princeton, NJ., Makenbaeva D; Group Director, Worldwide Health Economics and Outcomes Research Communications Lead, Bristol-Myers Squibb, Princeton, NJ. |
| المصدر: | American health & drug benefits [Am Health Drug Benefits] 2019 Nov; Vol. 12 (7), pp. 333-342. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Amplity Medical Communications Country of Publication: United States NLM ID: 101479877 Publication Model: Print Cited Medium: Print ISSN: 1942-2962 (Print) Linking ISSN: 19422962 NLM ISO Abbreviation: Am Health Drug Benefits Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: <2023-> : Cranbury, NJ : Amplity Medical Communications Original Publication: Long Valley, NJ : Engage Healthcare Communications, LLC |
| مستخلص: | Background: Imatinib, a first-generation tyrosine kinase inhibitor (TKI), and the newer second-generation TKIs have dramatically improved outcomes for patients with chronic myelogenous leukemia (CML). A previous model estimated the potential cost-savings over the next 2 years after the loss of patent exclusivity for imatinib in the United States in 2016 and its availability in a generic form. Payers have indeed realized meaningful savings, but it took 2 years for the prices of generic imatinib to decline substantially. Objective: To quantify the cost-savings for a US health plan from the passive substitution of generic imatinib and the impact of step-edit therapy with the use of generic imatinib before coverage of a second-generation TKI. Methods: We updated the previously published model utilizing hypothetical 1-million-member commercial and Medicare plans to include current TKI use and pricing combined with recent epidemiologic data. Regression models were used to project utilization to 5 years after the loss of imatinib's patent exclusivity. We compared generic imatinib costs with a scenario in which generic imatinib was not available. The impact of a step-edit therapy restriction was explored for patients with incident CML. The analyses were repeated for the entire US population based on national census data. Results: The 1-million-member commercial plan saved $0.5 million (3%) from pharmacy spending on TKIs in year 1 and $3.9 million (19%) in year 2 after the loss of patent exclusivity. The projected savings significantly increased to $7.8 million (37%), $8.3 million (39%), and $8.6 million (40%) in years 3, 4, and 5, respectively. Step-edits strategies were projected to result in small incremental savings of $0.3 million (1.5%) annually in years 3 to 5. The 1-million-member Medicare plan saved $1.7 million (3%) in year 1 and $14.1 million (19%) in year 2. The projected savings were $27.8 million (37%), $29.5 million (39%), and $30.8 million (40%), with step-edit estimated to add only $0.9 million (1.2%) annually in years 3 to 5. Generic imatinib saved US payers $2.5 billion (13% of the total spending on TKIs) in years 1 and 2. In years 3 to 5, the cumulative projected savings totaled $12.2 billion, and the savings were expected to grow to 39% as a result of passive generic imatinib substitution, with only 1.7% additional savings from step-edit restriction. Conclusions: As a result of a lower price for generic imatinib relative to the brand-name version of the drug, substantial cost-savings to US payers over the next 3 years are expected without step-edit formulary management restrictions. Cost-saving strategies, including formulary management restrictions, should adhere to evidence-based guidelines to ensure the appropriate use of generic imatinib and all available TKIs, with the objective to maintain positive outcomes and, in turn, increase the value of patient care. (Copyright © 2019 by Engage Healthcare Communications, LLC.) |
| References: | J Am Board Fam Med. 2013 Jan-Feb;26(1):93-5. (PMID: 23288287) Curr Hematol Malig Rep. 2018 Jun;13(3):202-211. (PMID: 29687320) Health Aff (Millwood). 2009 Jul-Aug;28(4):w533-43. (PMID: 19443477) Am Health Drug Benefits. 2015 Dec;8(9):472-80. (PMID: 26834933) J Med Econ. 2014 Feb;17(2):89-98. (PMID: 24188054) J Med Econ. 2017 Sep;20(9):1007-1012. (PMID: 28681664) Blood. 2011 Apr 7;117(14):3733-6. (PMID: 21346253) Am Health Drug Benefits. 2019 Nov;12(7):333-342. (PMID: 32055281) Curr Med Res Opin. 2014 Jul;30(7):1345-52. (PMID: 24640967) J Clin Oncol. 2010 May 10;28(14):2381-8. (PMID: 20385986) Int J Hematol. 2002 Jul;76(1):35-43. (PMID: 12138893) Fed Regist. ;81(246):94058-183. (PMID: 28068048) J Dermatolog Treat. 2010 May;21(3):178-84. (PMID: 19821787) J Med Econ. 2018 Oct;21(10):1036-1040. (PMID: 30071761) |
| فهرسة مساهمة: | Keywords: chronic myelogenous leukemia (CML); cost-savings; formulary management; generic imatinib; pharmacy spending; prior authorization; step-edits; tyrosine kinase inhibitors (TKIs) |
| تواريخ الأحداث: | Date Created: 20200215 Latest Revision: 20240328 |
| رمز التحديث: | 20240329 |
| مُعرف محوري في PubMed: | PMC6996618 |
| PMID: | 32055281 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1942-2962 |
|---|